Advances in physiology, design and development of novel medications changing the landscape of obesity pharmacotherapy
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Advances in physiology, design and development of novel medications changing the landscape of obesity pharmacotherapy
Authors
Keywords
-
Journal
METABOLISM-CLINICAL AND EXPERIMENTAL
Volume 142, Issue -, Pages 155531
Publisher
Elsevier BV
Online
2023-03-03
DOI
10.1016/j.metabol.2023.155531
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Adverse Events Related to Tirzepatide
- (2023) Rahul Mishra et al. Journal of the Endocrine Society
- Pharmacotherapy of obesity: an update on the available medications and drugs under investigation
- (2023) Marlene Chakhtoura et al. EClinicalMedicine
- Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes
- (2022) Dominik Dahl et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis
- (2022) Naveed Sattar et al. NATURE MEDICINE
- Structural determinants of dual incretin receptor agonism by tirzepatide
- (2022) Bingfa Sun et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial
- (2022) Amalia Gastaldelli et al. Lancet Diabetes & Endocrinology
- Updated Meta-Analysis Assessing the Cardiovascular Efficacy of Tirzepatide
- (2022) Dimitrios Patoulias et al. AMERICAN JOURNAL OF CARDIOLOGY
- Tirzepatide Once Weekly for the Treatment of Obesity
- (2022) Ania M. Jastreboff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction
- (2022) Michael A. Nauck et al. Cardiovascular Diabetology
- Efficacy and safety of tirzepatide as novel treatment for type 2 diabetes: A systematic review and meta-analysis of randomized clinical trials
- (2022) Hikmat Permana et al. Diabetes & Metabolic Syndrome-Clinical Research & Reviews
- Tirzepatide for the treatment of obesity: Rationale and design of the SURMOUNT clinical development program
- (2022) Carel W. le Roux et al. Obesity
- Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus
- (2022) Juan J. Gorgojo-Martínez et al. Journal of Clinical Medicine
- Once-Weekly Semaglutide in Adults with Overweight or Obesity
- (2021) John P.H. Wilding et al. NEW ENGLAND JOURNAL OF MEDICINE
- What Is Weight Loss After Bariatric Surgery Expressed in Percentage Total Weight Loss (%TWL)? A Systematic Review
- (2021) Anne-Sophie van Rijswijk et al. OBESITY SURGERY
- Targeting Energy Expenditure—Drugs for Obesity Treatment
- (2021) Carlos M. Jimenez-Munoz et al. Pharmaceuticals
- Closing obesity care gaps and achieving health equity for people living with obesity
- (2021) Ximena Ramos Salas European Journal of Internal Medicine
- Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial
- (2021) Julio Rosenstock et al. LANCET
- Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial
- (2021) Bernhard Ludvik et al. LANCET
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
- (2021) Juan P. Frías et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Function of Gastrointestinal Hormones in Obesity—Implications for the Regulation of Energy Intake
- (2021) Mona Farhadipour et al. Nutrients
- Efficacy of Semaglutide in a Subcutaneous and an Oral Formulation
- (2021) Juris J. Meier Frontiers in Endocrinology
- Novel Noninvasive Approaches to the Treatment of Obesity: From Pharmacotherapy to Gene Therapy
- (2021) Angeliki M Angelidi et al. ENDOCRINE REVIEWS
- Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial
- (2021) Stefano Del Prato et al. LANCET
- Anti-obesity drug discovery: advances and challenges
- (2021) Timo D. Müller et al. NATURE REVIEWS DRUG DISCOVERY
- Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice
- (2021) Sean Wharton et al. POSTGRADUATE MEDICINE
- Association between weight loss and serum biomarkers with risk of incident cancer in the Longitudinal Assessment of Bariatric Surgery cohort
- (2020) Andrea M. Stroud et al. Surgery for Obesity and Related Diseases
- How May GIP Enhance the Therapeutic Efficacy of GLP-1?
- (2020) Ricardo J. Samms et al. TRENDS IN ENDOCRINOLOGY AND METABOLISM
- GLP1 agonists beyond glycemic control—redefining their role
- (2020) Subhankar Chowdhury et al. International Journal of Diabetes in Developing Countries
- Intensive Weight Loss Intervention and Cancer Risk in Adults with Type 2 Diabetes: Analysis of the Look AHEAD Randomized Clinical Trial
- (2020) et al. Obesity
- Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study
- (2019) Natasha C. Bergmann et al. DIABETOLOGIA
- What is driving global obesity trends? Globalization or “modernization”?
- (2019) Ashley Fox et al. Globalization and Health
- Longer‐term liraglutide administration at the highest dose approved for obesity increases reward‐related orbitofrontal cortex activations to food cues: Implications for plateauing weight loss in response to anti‐obesity therapies
- (2019) Olivia M. Farr et al. DIABETES OBESITY & METABOLISM
- Will medications that mimic gut hormones or target their receptors eventually replace bariatric surgery?
- (2019) Alexander Kokkinos et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- The influence of Glucose-dependent Insulinotropic Polypeptide (GIP) on human adipose tissue and fat metabolism: Implications for obesity, type 2 diabetes and Non-Alcoholic Fatty Liver Disease (NAFLD)
- (2019) Sravan K. Thondam et al. PEPTIDES
- Novel dual GLP-1/GIP receptor agonists show neuroprotective effects in Alzheimer's and Parkinson's disease models
- (2018) Christian Hölscher NEUROPHARMACOLOGY
- Obesity as a risk factor for Alzheimer's disease: weighing the evidence
- (2017) S. Alford et al. Obesity Reviews
- GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-controlled trial
- (2016) Olivia M. Farr et al. DIABETOLOGIA
- AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY
- (2016) W. Timothy Garvey et al. Endocrine Practice
- Metabolic health and weight: Understanding metabolically unhealthy normal weight or metabolically healthy obese patients
- (2016) Hannah Mathew et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Short-term administration of the GLP-1 analog liraglutide decreases circulating leptin and increases GIP levels and these changes are associated with alterations in CNS responses to food cues: A randomized, placebo-controlled, crossover study
- (2016) Olivia M. Farr et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial
- (2016) Lancet Diabetes & Endocrinology
- Peripheral Mechanisms in Appetite Regulation
- (2015) Michael Camilleri GASTROENTEROLOGY
- Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline
- (2015) Caroline M. Apovian et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Narrative Review: The Role of Leptin in Human Physiology: Emerging Clinical Applications
- (2013) Theodore Kelesidis ANNALS OF INTERNAL MEDICINE
- Metabolic complications of obesity
- (2013) Sue D. Pedersen BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM
- Food and Drug Administration's Obesity Drug Guidance Document
- (2012) Eric Colman CIRCULATION
- Anti-obesity drugs: past, present and future
- (2012) R. J. Rodgers et al. Disease Models & Mechanisms
- Leptin in human physiology and pathophysiology
- (2011) Christos S. Mantzoros et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- Leptin in human physiology and therapeutics
- (2010) Tina A. Dardeno et al. FRONTIERS IN NEUROENDOCRINOLOGY
- Effects of peripheral administration of synthetic human glucose-dependent insulinotropic peptide (GIP) on energy expenditure and subjective appetite sensations in healthy normal weight subjects and obese patients with type 2 diabetes
- (2009) C. Daousi et al. CLINICAL ENDOCRINOLOGY
- Mechanisms of Disease: the role of gastrointestinal hormones in appetite and obesity
- (2008) Royce P Vincent et al. Nature clinical practice. Gastroenterology & hepatology
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search